Doximity (BSP:D2OC34) Research & Development: R$704 Mil (TTM As of Mar. 2026)


BSP:D2OC34 Doximity Inc BSP:D2OC34
62 GF Score
Price R$17.14
GF Value R$39.99
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Doximity Research & Development?

Doximity BSP:D2OC34 62 Research & Development is R$704 Mil as of Mar. 2026. GuruFocus rates BSP:D2OC34 with a GF Score™ of 62/100 and a GF Value™ of R$39.99 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Doximity's Research & Development for the three months ended in Mar. 2026 was R$205 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was R$704 Mil.

Doximity  (BSP:D2OC34) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Doximity Research & Development Related Terms

Doximity Research & Development Historical Data

* Premium members only.

The historical data trend for Doximity's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Doximity Research & Development Chart

Doximity Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 310.28 417.66 408.26 535.72 683.52

Doximity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.82 148.62 161.97 188.74 204.51
BSP:D2OC34
62GF Score
Doximity Inc BSP:D2OC34
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Doximity Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$704 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R$704 Mil mean?
Doximity (BSP:D2OC34) has a Research & Development of R$704 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Doximity and its competitors.
Is Doximity's Research & Development too high?
Doximity's current Research & Development is R$704 Mil. Overall, Doximity has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's Research & Development compare to WAY and TXG?
Doximity's Research & Development of R$704 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Doximity and its competitors. Doximity's current Research & Development is R$704 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (BSP:D2OC34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$39.99, compared to a current price of R$17.14 — trading 57.1% below its estimated fair value. The current Research & Development is R$704 Mil. Doximity's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Doximity (BSP:D2OC34), the current Research & Development is R$704 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Doximity (BSP:D2OC34) Overvalued in 2026?

Based on GuruFocus' analysis, Doximity stock appears to be undervalued. The current stock price of R$17.14 is trading 57.1% below its estimated GF Value™ of R$39.99. GuruFocus considers Doximity to be Significantly Undervalued.

Key valuation signals for BSP:D2OC34:

  • Research & Development: R$704 Mil
  • GF Value™: R$39.99 vs. price of R$17.14 (57.1% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the BSP:D2OC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Doximity Business Description

Other Exchanges DOCS:USA
Address 500 3rd Street, Suite 510, San Francisco, CA, USA, 94107
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
62GF Score

Get the complete analysis for BSP:D2OC34

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$17.14
Price
R$39.99
GF Value